EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pattern and Clinical Significance of CA19 ‐9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors

Nina Schraps iD, Anne Menz, Florian Viehweger, Seyma Büyücek iD, David Dum, Ria Schlichter, Andrea Hinsch, Christoph Fraune, Christian Bernreuther, Martina Kluth, Claudia Hube-Magg iD, Katharina Möller und 20 weitere

Cancer Medicine · 2026-03 · 15 (3)

DOI: 10.1002/cam4.71710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.03.2026. Verfasst von Nina Schraps und 31 weiteren Autor:innen. Beteiligte Einrichtung: General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: CA-19-9 Antigen, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbohydrate antigen 19–9 (CA19‐9) is a cell surface glycoprotein widely used as a diagnostic and prognostic serum marker for monitoring pancreatic cancer. The aim of this study was to evaluate the prevalence and clinical relevance of CA19‐9 expression in human cancer.

Methods

To comprehensively determine the prevalence and clinical relevance of CA19‐9 expression in cancer, a tissue microarray containing 14,966 samples from 134 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.

Results

The staining results were categorized into four groups according to the percentage of CA19‐9‐positive tumor cells and the staining intensity. At least an occasional CA19‐9 positivity was found in 79 of 134 tumor categories with 66 containing at least one strongly positive case. CA19‐9 positivity was most frequent in biliopancreatic adenocarcinomas (84.4%–95.4%), adenocarcinomas of the upper and lower gastrointestinal tract (54.7%–74.4%), embryonal carcinomas of the testis (93.5%), and endometrioid endometrial carcinomas (87.5%). High CA19‐9 staining was associated with advanced pT‐stage, pN1, L1 ( p < 0.0001 each), V1 ( p = 0.0239), mismatch repair protein deficiency ( p = 0.0067), and BRAF V600E mutation ( p = 0.0005) in colorectal adenocarcinoma. Reduced CA19‐9 staining was associated with distant metastasis ( p = 0.0067) in clear cell renal cell carcinoma, advanced pT‐stage ( p = 0.0277) in papillary renal cell carcinoma, high grade ( p = 0.0129) in breast cancer and with invasive tumor growth (pTa vs. pT2‐4, p < 0.0001) and high grade ( p = 0.0367) in urothelial carcinoma.

Conclusions

It is concluded that a high CA19‐9 expression, as found in pancreatic adenocarcinoma, occurs in subsets of various other cancer types. Patients with such tumors could potentially benefit from CA19‐9 serum monitoring, for example in terms of response to treatment, recurrence or predicting prognosis. Cancer type dependent associations between high or low CA19‐9 expression and aggressive tumor phenotype are in line with the complex and variable functional role described for CA19‐9 in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CA-19-9 AntigenBiomarkers, TumorNeoplasmsHumansTissue Array AnalysisFemaleMaleImmunohistochemistryPrognosisNeoplasm StagingMiddle Aged

Stichwörter der Autor:innen

CA19‐9IHCbiomarkercancercarbohydrate antigen 19–9tissue microarray

Substanzen

CA-19-9 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany.
  • Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany.

ORCID-Profile: Nina Schraps, Seyma Büyücek, Claudia Hube-Magg, Maximilian Lennartz, Ronald Simon, Sarah Minner

Zitieren

APA

Schraps, N., Menz, A., Viehweger, F., Büyücek, S., Dum, D., Schlichter, R., Hinsch, A., Fraune, C., Bernreuther, C., Kluth, M., Hube-Magg, C., Möller, K., Reiswich, V., Luebke, A. M., Lebok, P., Weidemann, S., Sauter, G., Lennartz, M., Jacobsen, F., …, & Freytag, M. (2026). Pattern and Clinical Significance of CA19 ‐9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71710

Vancouver

Schraps N, Menz A, Viehweger F, Büyücek S, Dum D, Schlichter R, et al. Pattern and Clinical Significance of CA19 ‐9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71710

BibTeX
@article{Schraps2026,
  author = {Schraps, Nina and Menz, Anne and Viehweger, Florian and Büyücek, Seyma and Dum, David and Schlichter, Ria and Hinsch, Andrea and Fraune, Christoph and Bernreuther, Christian and Kluth, Martina and Hube-Magg, Claudia and Möller, Katharina and Reiswich, Viktor and Luebke, Andreas M and Lebok, Patrick and Weidemann, Sören and Sauter, Guido and Lennartz, Maximilian and Jacobsen, Frank and Clauditz, Till S and Marx, Andreas H and Simon, Ronald and Steurer, Stefan and Mercanoglu, Baris and Melling, Nathaniel and Hackert, Thilo and Burandt, Eike and Gorbokon, Natalia and Minner, Sarah and Krech, Till and Lutz, Florian and Freytag, Morton},
  title = {Pattern and Clinical Significance of CA19 ‐9 Expression in Human Cancer: A Tissue Microarray Study on 14,966 Tumors},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cam4.71710}
}
Kostenlos starten →